August 12, 2021
SAN RAMON, Calif. — CooperVision MiSight 1 day contact lenses have received approval by the Chinese National Medical Products Administration (NMPA). The soft contact lenses have become the first indicated product of any type in China that may slow the progression of axial length.1
“Everyone at CooperVision is committed to combatting the increasing prevalence and severity of myopia among children. It has become one of the world’s most pressing global eye health issues — with implications for generations to come,” said Daniel G. McBride, President, CooperVision. “We are enthusiastic about MiSight 1 day contact lenses’ impact in partnership with highly knowledgeable ophthalmologists and health care leaders across China. This development will further expand the global reach of our evidence-based technologies and clinical successes.”
In China, myopia prevalence has increased at a significant rate in recent years. While 14.3% of six year-old children are myopic,2 prevalence soars to 80.5% among high school students.2 Myopia prevalence in China is up 2.5% from 2019 to 2020, which is commonly attributed to children’s increased indoor time and digital screen use. Myopia rates in primary schools are rising rapidly as children age, from 12.9% in the first grade2 to 59.6% in the sixth grade.2 On average, myopia increased by 9.3 percentage points per grade.2
CooperVision’s MiSight 1 day contact lenses are now available in more than 25 countries. They were the first and remain the only U.S. FDA-approved* soft contact lens designed for myopia control with a proven ability to slow the progression of nearsightedness in children aged 8-12 at the initiation of treatment.†3
“Alongside increasing demand for MiSight 1 day are stories of success originating from the Americas, Europe, and Asia-Pacific. We’re constantly hearing from eye care professionals about how the lens is helping grow their business and from partners about how our efforts have galvanized the eye care community to take on myopia. And of course, we hear every day about the difference that MiSight 1 day is making in the lives of children — the most important outcome of all,” McBride said.
1 MiSight is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. Meanwhile, it has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus, and expecting to slow down the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with intermediate title or above and conduct regular check. It must be used in strict accordance with the IFU requirements.
2 National Health Commission. 13 July 2021. Myopia survey conducted from September to December 2020, covering 8,604 schools across the country and screening a total of 2.477 million students. Retrieved from: http://www.nhc.gov.cn/xwzb/
3 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
* U.S. Indications for Use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
† Compared to a single vision 1 day lens over a 3-year period.